JP2021502388A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502388A5
JP2021502388A5 JP2020526068A JP2020526068A JP2021502388A5 JP 2021502388 A5 JP2021502388 A5 JP 2021502388A5 JP 2020526068 A JP2020526068 A JP 2020526068A JP 2020526068 A JP2020526068 A JP 2020526068A JP 2021502388 A5 JP2021502388 A5 JP 2021502388A5
Authority
JP
Japan
Prior art keywords
salt
compound
formula
combination
suitable substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020526068A
Other languages
English (en)
Other versions
JPWO2019094773A5 (ja
JP2021502388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060102 external-priority patent/WO2019094773A1/en
Publication of JP2021502388A publication Critical patent/JP2021502388A/ja
Publication of JP2021502388A5 publication Critical patent/JP2021502388A5/ja
Publication of JPWO2019094773A5 publication Critical patent/JPWO2019094773A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 構造:
    Figure 2021502388
    ;または
    Figure 2021502388

    (式中、R、R2−5、R、R、及びXは、本明細書に記載及び/または図示される好適な置換基及び部分の任意の組み合わせから選択される)を含む化合物;
    またはその塩。
JP2020526068A 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法 Pending JP2021502388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584473P 2017-11-10 2017-11-10
US62/584,473 2017-11-10
PCT/US2018/060102 WO2019094773A1 (en) 2017-11-10 2018-11-09 Ash1l inhibitors and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2021502388A JP2021502388A (ja) 2021-01-28
JP2021502388A5 true JP2021502388A5 (ja) 2021-12-23
JPWO2019094773A5 JPWO2019094773A5 (ja) 2022-03-03

Family

ID=66432988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法
JP2024002472A Pending JP2024041896A (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002472A Pending JP2024041896A (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Country Status (6)

Country Link
US (6) US10632209B2 (ja)
EP (2) EP3706737A4 (ja)
JP (3) JP7424637B2 (ja)
CN (2) CN111542318A (ja)
CA (2) CA3082086A1 (ja)
WO (2) WO2019094773A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN111542318A (zh) 2017-11-10 2020-08-14 密歇根大学董事会 Ash1l降解剂及用其进行治疗的方法
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
JP7426124B2 (ja) * 2019-06-12 2024-02-01 シャンハイテック ユニバーシティ Alkタンパク質レギュレーター、及びその抗腫瘍における使用
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
CN113004251B (zh) * 2021-03-05 2022-09-27 郑州大学第一附属医院 含2-硝基咪唑的喹唑啉类衍生物及其应用
CN115960104A (zh) * 2021-10-09 2023-04-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
KR20240051859A (ko) * 2022-10-13 2024-04-22 한미약품 주식회사 Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861A (en) 1848-10-17 Locking umbrella and parasol
US510A (en) 1837-12-07 soeel
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5863A (en) 1848-10-17 Matthias p
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1990009381A1 (en) 1989-02-08 1990-08-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5391452A (en) 1993-08-02 1995-02-21 Xerox Corporation Polyester toner and developer compositions
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en) 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BR9807815A (pt) 1997-02-03 2000-03-08 Pfizer Prod Inc Derivados de ácido arilsulfonilamino-hidroxâmico
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
HUP0000657A3 (en) 1997-02-11 2000-10-30 Pfizer N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EA002490B1 (ru) 1997-08-08 2002-06-27 Пфайзер Продактс Инк. Производные арилоксиарилсульфониламиногидроксамовой кислоты
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
ATE293599T1 (de) * 1997-12-24 2005-05-15 Aventis Pharma Gmbh Indolderivate als faktor xa inhibitoren
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6114361A (en) 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP4505566B2 (ja) 2004-09-30 2010-07-21 愛知県 肺癌治療剤
US20080233101A1 (en) 2005-09-15 2008-09-25 The Regents Of The University Of California RNA-mediated epigenetic regulation of gene transcription
US7932284B2 (en) 2006-01-24 2011-04-26 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
RU2465271C2 (ru) * 2006-07-18 2012-10-27 Антиб Терапьютикс Инк. 4-гидрокситиобензамидные производные лекарственных веществ
CA2674895A1 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml)
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
WO2009015067A2 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
CA2828212A1 (en) * 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
US9889180B2 (en) 2012-11-19 2018-02-13 Agency For Science, Technology And Research Method of treating cancer
AU2014236947A1 (en) * 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MX2015012456A (es) * 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
MX2016009976A (es) * 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Derivados de diazepam y sus usos.
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR20220101015A (ko) 2014-04-14 2022-07-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP2018527336A (ja) 2015-08-10 2018-09-20 ファイザー・インク 3−インドール置換誘導体、医薬組成物、および使用方法
US20170158702A1 (en) 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
RU2752677C2 (ru) 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка вет
EP3445760B1 (en) 2016-04-22 2022-02-23 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
CA3047784A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
CN111542318A (zh) 2017-11-10 2020-08-14 密歇根大学董事会 Ash1l降解剂及用其进行治疗的方法

Similar Documents

Publication Publication Date Title
JP2021502388A5 (ja)
JP2018024670A5 (ja)
JP2021502386A5 (ja)
JP2018024682A5 (ja)
JP2010501534A5 (ja)
JP2009535462A5 (ja)
JP2019194236A5 (ja)
JP2023115329A5 (ja)
JP2019089762A5 (ja)
JP2020042034A5 (ja)
JP2020010717A5 (ja)
JP2018150298A5 (ja)
JP2017222697A5 (ja)
JP2018520455A5 (ja)
JP2014156468A5 (ja)
JP2015522045A5 (ja)
JP2016518328A5 (ja)
JP2015199738A5 (ja)
JP2017537066A5 (ja)
JP2018521020A5 (ja)
JP2018203763A5 (ja)
JP2010511721A5 (ja)
JP2018116258A5 (ja)
JP2011016798A5 (ja)
JP2018506302A5 (ja)